<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
  <channel>
    <title>Weight-loss drugs</title>
    <link>https://www.wfyi.org/tags/weight-loss-drugs</link>
    <description>Weight-loss drugs</description>
    <language>en-US</language>
    <copyright>Copyright</copyright>
    <lastBuildDate>Thu, 07 Aug 2025 04:00:00 GMT</lastBuildDate>
    <atom:link href="https://www.wfyi.org/tags/weight-loss-drugs.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Marion county lawsuits allege side effects of weight loss drugs were downplayed by drug companies</title>
      <link>https://www.wfyi.org/wfyi-news/2025-08-07/marion-county-lawsuits-allege-side-effects-of-weight-loss-drugs-were-downplayed-by-drug-companies</link>
      <description>A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side effects of its obesity and diabetes drugs.</description>
      <pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
      <guid>https://www.wfyi.org/wfyi-news/2025-08-07/marion-county-lawsuits-allege-side-effects-of-weight-loss-drugs-were-downplayed-by-drug-companies</guid>
      <dc:creator>Benjamin Thorp</dc:creator>
      <media:thumbnail url="https://npr.brightspotcdn.com/dims4/default/3f5ba8b/2147483647/strip/false/crop/1500x1001+0+0/resize/300x200!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Fnpr-brightspotcdn_ODWMGc1d.jpg" />
      <media:content type="image/jpeg" url="https://npr.brightspotcdn.com/dims4/default/ac9846a/2147483647/strip/false/crop/1500x1001+0+0/resize/791x528!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Fnpr-brightspotcdn_ODWMGc1d.jpg" />
    </item>
    <item>
      <title>Indiana joins states calling for the FDA to clamp down on counterfeit weight loss drugs</title>
      <link>https://www.wfyi.org/health/2025-03-03/states-are-calling-for-the-fda-to-clamp-down-on-counterfeit-weight-loss-drugs</link>
      <description>Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration to take action against "bad actors" selling counterfeit weight loss drugs.</description>
      <pubDate>Mon, 03 Mar 2025 05:00:00 GMT</pubDate>
      <guid>https://www.wfyi.org/health/2025-03-03/states-are-calling-for-the-fda-to-clamp-down-on-counterfeit-weight-loss-drugs</guid>
      <dc:creator>Benjamin Thorp</dc:creator>
      <media:thumbnail url="https://npr.brightspotcdn.com/dims4/default/165d7d0/2147483647/strip/false/crop/1500x1000+0+0/resize/300x200!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Flilly2-lc-cfsm7llm.jpg" />
      <media:content type="image/jpeg" url="https://npr.brightspotcdn.com/dims4/default/3ceb3ba/2147483647/strip/false/crop/1500x1000+0+0/resize/792x528!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Flilly2-lc-cfsm7llm.jpg" />
    </item>
    <item>
      <title>The Checkup: Ozempic babies? Explaining unexpected pregnancies on GLP-1 drugs</title>
      <link>https://www.wfyi.org/health/2024-04-26/the-checkup-ozempic-babies-explaining-unexpected-pregnancies-on-glp-1-drugs</link>
      <description>The way Ozempic and other GLP-1 drugs that spur weight loss work and interact with birth control may be behind some unexpected pregnancies.</description>
      <pubDate>Fri, 26 Apr 2024 04:00:00 GMT</pubDate>
      <guid>https://www.wfyi.org/health/2024-04-26/the-checkup-ozempic-babies-explaining-unexpected-pregnancies-on-glp-1-drugs</guid>
      <media:thumbnail url="https://npr.brightspotcdn.com/dims4/default/33025a9/2147483647/strip/false/crop/1500x1000+0+0/resize/300x200!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Fpexels-pixabay-161534.jpg" />
      <media:content type="image/jpeg" url="https://npr.brightspotcdn.com/dims4/default/7dcff79/2147483647/strip/false/crop/1500x1000+0+0/resize/792x528!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Fpexels-pixabay-161534.jpg" />
    </item>
    <item>
      <title>FDA approves new version of diabetes drug Mounjaro for weight loss</title>
      <link>https://www.wfyi.org/health/2023-11-08/fda-approves-new-version-of-diabetes-drug-mounjaro-for-weight-loss</link>
      <description>Federal regulators say a new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug. The Food and Drug Administration approved Zepbound on Wednesday. The drug has been shown to help dieters lose about a quarter of their body weight, or 60 pounds. It is the latest diabetes drug approved for weight loss, joining Novo Nordisk’s Wegovy, a high-dose version of Ozempic. Short supply and high costs have limited access to both medications. The FDA approved the new drug for people considered obese or for those who are overweight and have a weight-related health condition.</description>
      <pubDate>Wed, 08 Nov 2023 05:00:00 GMT</pubDate>
      <guid>https://www.wfyi.org/health/2023-11-08/fda-approves-new-version-of-diabetes-drug-mounjaro-for-weight-loss</guid>
      <dc:creator>Associated Press</dc:creator>
      <media:thumbnail url="https://npr.brightspotcdn.com/dims4/default/461d504/2147483647/strip/false/crop/1500x1000+0+0/resize/300x200!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Fap23285764069391.jpg" />
      <media:content type="image/jpeg" url="https://npr.brightspotcdn.com/dims4/default/97e1913/2147483647/strip/false/crop/1500x1000+0+0/resize/792x528!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Fap23285764069391.jpg" />
    </item>
    <item>
      <title>Ozempic hype forces employer calls on obesity coverage</title>
      <link>https://www.wfyi.org/health/2023-10-02/ozempic-hype-forces-employer-calls-on-obesity-coverage</link>
      <description>The quick rise in popularity of the diabetes drugs used for weight loss over the last two years caught many employers flat footed. Now, employers are scrambling to find solutions to help improve worker health while simultaneously keeping a lid on rising health care spending.</description>
      <pubDate>Mon, 02 Oct 2023 04:00:00 GMT</pubDate>
      <guid>https://www.wfyi.org/health/2023-10-02/ozempic-hype-forces-employer-calls-on-obesity-coverage</guid>
      <dc:creator>Dan Gorenstein, Alex Olgin – Tradeoffs</dc:creator>
      <media:thumbnail url="https://npr.brightspotcdn.com/dims4/default/2e515f6/2147483647/strip/false/crop/1500x1000+0+0/resize/300x200!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Fpexels-nataliya-vaitkevich-6941883.jpg" />
      <media:content type="image/jpeg" url="https://npr.brightspotcdn.com/dims4/default/9a7796b/2147483647/strip/false/crop/1500x1000+0+0/resize/792x528!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Fpexels-nataliya-vaitkevich-6941883.jpg" />
    </item>
    <item>
      <title>Eli Lilly releases more data for new obesity drug, moving toward fast-track approval</title>
      <link>https://www.wfyi.org/health/2023-04-27/eli-lilly-releases-more-data-for-new-obesity-drug-moving-toward-fast-track-approval</link>
      <description>There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.</description>
      <pubDate>Thu, 27 Apr 2023 04:00:00 GMT</pubDate>
      <guid>https://www.wfyi.org/health/2023-04-27/eli-lilly-releases-more-data-for-new-obesity-drug-moving-toward-fast-track-approval</guid>
      <dc:creator>NPR</dc:creator>
      <media:thumbnail url="https://npr.brightspotcdn.com/dims4/default/0339578/2147483647/strip/false/crop/1500x843+0+0/resize/300x169!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Feli-lilly-headquarters-wide-5753500c5e5ee0fac4e0881b5eeb28c1fb85abce.jpg" />
      <media:content type="image/jpeg" url="https://npr.brightspotcdn.com/dims4/default/368e300/2147483647/strip/false/crop/1500x843+0+0/resize/792x445!/quality/90/?url=http%3A%2F%2Fnpr-brightspot.s3.amazonaws.com%2Flegacy%2Ffiles%2Fwfyi%2Farticles%2Foriginal%2Feli-lilly-headquarters-wide-5753500c5e5ee0fac4e0881b5eeb28c1fb85abce.jpg" />
    </item>
  </channel>
</rss>
